Advances in Therapy

, 26:462 | Cite as

Comparison of inhaled and intravenous milrinone in patients with pulmonary hypertension undergoing mitral valve surgery

  • Hongmei Wang
  • Ming GongEmail author
  • Bin Zhou
  • Anlu Dai
Original Research



Increased pulmonary vascular resistance (PVR) is detrimental to cardiac output in postoperative cardiac-surgery patients. The aim of this study was to investigate the postoperative hemodynamic effects of milrinone inhalation, and determine whether it has a selective effect of pulmonary vasodilation in patients with pulmonary hypertension undergoing mitral valve replacement surgery.


In this study, 48 patients with pulmonary hypertension who underwent mitral valve replacement surgery were included. Patients were randomly divided into two groups with 24 patients in each: the inhaled group and the control group (intravenous [i.v.] milrinone). In the inhaled group, milrinone was administered with a jet nebulizer, and nebulized for 4 hours. In the control group, patients received a bolus of 50 μg/kg i.v. milrinone, then received a continuous milrinone infusion, 0.5 μg/kg/min, for 4 hours. A number of hemodynamic changes in all patients were evaluated.


With milrinone administration, mean pulmonary artery pressure (MPAP) and PVR showed a comparable decrease in both groups. However, after initiation of milrinone, both mean arterial pressure and systemic vascular resistance in the inhaled group were significantly higher than in the control group. MPAP and PVR returned to baseline values 60 minutes after termination of milrinone inhalation. In addition, in the inhaled group, there was a reduction in intrapulmonary shunt fraction (Qs/Qt), with an improvement in PaO2/FiO2 (arterial oxygen tension/fraction of inspired oxygen).


The major advantage of inhaled milrinone is its pulmonary selectivity, thereby avoiding systemic side effects and ventilationperfusion mismatch. Inhaled milrinone is an effective pulmonary vasodilator and appears to be an alternative promising approach in addressing the problem of right-ventricular decompensation following cardiopulmonary bypass.


cardiopulmonary bypass inhaled milrinone mitral valve surgery pulmonary hypertension pulmonary vascular resistance 


  1. 1.
    Roques F, Nashef SA, Michel P, et al. Risk factors and outcome in European cardiac surgery: analysis of the EuroSCORE multinational database of 19030 patients. Eur J Cardiothorac Surg. 1999;15:816–822.PubMedCrossRefGoogle Scholar
  2. 2.
    Bando K, Turrentine MW, Sharp TG, et al. Pulmonary hypertension after operations for congenital heart disease: analysis of risk factors and management. J Thorac Cardiovasc Surg. 1996;112:1600–1607.PubMedCrossRefGoogle Scholar
  3. 3.
    Riedel B. The pathophysiology and management of perioperative pulmonary hypertension with specific emphasis on the period following cardiac surgery. Int Anesthesiol Clin. 1999;37:55–79.PubMedCrossRefGoogle Scholar
  4. 4.
    Voswinckel R, Reichenberger F, Enke B, et al. Acute effects of the combination of sildenafil and inhaled treprostinil on haemodynamics and gas exchange in pulmonary hypertension. Pulm Pharmacol Ther. 2008;21:824–832.PubMedCrossRefGoogle Scholar
  5. 5.
    Evgenov OV, Kohane DS, Bloch KD, et al. Inhaled agonists of soluble guanylate cyclase induce selective pulmonary vasodilation. Am J Respir Crit Care Med. 2007;176:1138–1145.PubMedCrossRefGoogle Scholar
  6. 6.
    Levy JH, Bailey JM, Deeb GM. Intravenous milrinone in cardiac surgery. Ann Thorac Surg. 2002;73:325–330.PubMedCrossRefGoogle Scholar
  7. 7.
    Galiè N, Torbicki A, Barst R, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J. 2004;25:2243–2278.Google Scholar
  8. 8.
    Schulze-Neick I, Hartenstein P, Li J, et al. Intravenous sildenafil is a potent pulmonary vasodilator in children with congenital heart disease. Circulation. 2003;108(suppl. 1):II167–II173.PubMedGoogle Scholar
  9. 9.
    Foltz BD, Hessel EA 2nd, Ivey TD. The early course of pulmonary artery hypertension in patients undergoing mitral valve replacement with cardioplegic arrest. J Thorac Cardiovasc Surg. 1984;88:238–247.PubMedGoogle Scholar
  10. 10.
    Guarracino F, Cariello C, Danella A, et al. Right ventricular failure: physiology and assessment. Minerva Anestesiol. 2005;71:307–312.PubMedGoogle Scholar
  11. 11.
    Andrivet P, Cadranel J, Housset B, Herigault R, Harf A, Adnot S. Mechanisms of impaired arterial oxygenation in patients with liver cirrhosis and severe respiratory insufficiency. Effects of indomethacin. Chest. 1993;103:500–507.Google Scholar
  12. 12.
    Hoeper MM, Seyfarth HJ, Hoeffken G, et al. Experience with inhaled iloprost and bosentan in portopulmonary hypertension. Eur Respir J. 2007;30:1096–1102.PubMedCrossRefGoogle Scholar
  13. 13.
    Haraldsson A, Kieler-Jensen N, Ricksten SE. The additive pulmonary vasodilatory effects of inhaled prostacyclin and inhaled milrinone in postcardiac surgical patients with pulmonary hypertension. Anesth Analg. 2001;93:1439–1445.CrossRefGoogle Scholar
  14. 14.
    Lamarche Y, Perrault LP, Maltais S, Tetreault K, Lambert J, Denault AY. Preliminary experience with inhaled milrinone in cardiac surgery. Eur J Cardiothorac Surg. 2007;31:1081–1087.PubMedCrossRefGoogle Scholar
  15. 15.
    Sablotzki A, Starzmann W, Scheubel R, Grond S, Czeslick EG. Selective pulmonary vasodilation with inhaled aerosolized milrinone in heart transplant candidates. Can J Anaesth. 2005;52:1076–1082.PubMedCrossRefGoogle Scholar
  16. 16.
    Rossaint R, Falke KJ, López F, Slama K, Pison U, Zapol WM. Inhaled nitric oxide for the adult respiratory distress syndrome. N Engl J Med. 1993;328:399–405.PubMedCrossRefGoogle Scholar
  17. 17.
    Dhand R. Inhalation therapy in invasive and noninvasive mechanical ventilation. Curr Opin Crit Care. 2007;13:27–38.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Healthcare Communications 2009

Authors and Affiliations

  1. 1.Department of Anesthesiology, Second Affiliated Hospital, School of MedicineZhejiang UniversityHangzhouChina

Personalised recommendations